Form 4: Coya Therapeutics Director Dieter Weinand Granted Stock Options

Coya Therapeutics Director Dieter Weinand was granted 10,000 stock options with an exercise price of $5.65, vesting in one year.

Summary

• Director Dieter Weinand of Coya Therapeutics, Inc. (COYA) was granted 10,000 stock options.
• The grant date for these options is January 2, 2026.
• Each option has an exercise price of $5.65, allowing the purchase of Common Stock, par value $0.0001 per share.
• The options will vest 100% on January 2, 2027, which is the first anniversary of the grant date, contingent on Mr. Weinand's continuous service.
• The expiration date for these stock options is January 2, 2036.
• Following this transaction, Mr. Weinand directly beneficially owns 10,000 derivative securities.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates alignment of a director's interests with shareholders through equity compensation, a standard corporate governance practice. No negative implications are present.

Positives

• The granting of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a substantial window for potential value realization if the company's stock price appreciates.

Negatives

• No direct negatives are apparent from this routine insider transaction disclosure.

Risks

• The vesting of the options is subject to continuous service, meaning Mr. Weinand must remain a director for the options to fully vest.
• The value of the options is dependent on the future stock price of Coya Therapeutics exceeding the exercise price of $5.65.

Future Outlook

The options are structured to incentivize future performance, with full vesting contingent on continuous service for one year from the grant date. The long expiration date provides a significant window for the company's stock price to appreciate.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Coya Therapeutics, to attract and retain talent, align interests, and incentivize long-term value creation. This practice is standard for executive and director compensation across many publicly traded companies.

Comparison to Industry Standards

• The grant of 10,000 stock options to a director is within typical ranges for non-executive directors at small to mid-cap biotechnology companies, though specific comparisons would require detailed peer group analysis.
• A 10-year expiration period for stock options is a common industry standard, providing ample time for the options to become in-the-money.
• One-year cliff vesting for director options is also a common practice, ensuring a minimum period of service for the incentive to materialize.

Related Party Transactions

• This transaction is a direct equity grant to a director, which is a common form of related party compensation and is disclosed as required.

Stakeholder Impact

• Shareholders: Potential minor dilution if options are exercised in the future, but also improved alignment of director incentives with shareholder value creation.

Next Steps

• Continued service of Dieter Weinand as a Director of Coya Therapeutics.
• Vesting of the 10,000 stock options on January 2, 2027.
• Potential exercise of the options by Mr. Weinand between January 2, 2027, and January 2, 2036.

Key Dates

Keywords

Coya Therapeutics, COYA, Dieter Weinand, stock options, insider transaction, Form 4, director compensation, equity grant, vesting